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Neutrophils participate in the maintenance of host integrity by releasing various cytotoxic proteins during degranulation. Due
to recent advances, a major role has been attributed to neutrophil-derived cytokine secretion in the initiation, exacerbation, and
resolution of inflammatory responses. Because the release of neutrophil-derived products orchestrates the action of other immune
cells at the infection site and, thus, can contribute to the development of chronic inflammatory diseases, we aimed to investigate
in more detail the spatiotemporal regulation of neutrophil-mediated release mechanisms of proinflammatory mediators. Purified
human neutrophils were stimulated for different time points with lipopolysaccharide. Cells and supernatants were analyzed by
flow cytometry techniques and used to establish secretion profiles of granules and cytokines. To analyze the link between cytokine
release and degranulation time series, we propose an original strategy based on linear fitting, which may be used as a guideline,
to (i) define the relationship of granule proteins and cytokines secreted to the inflammatory site and (ii) investigate the spatial
regulation of neutrophil cytokine release. The model approach presented here aims to predict the correlation between neutrophil-
derived cytokine secretion and degranulation and may easily be extrapolated to investigate the relationship between other types of
time series of functional processes.
1. Introduction
Historically, neutrophils were described as simple profes-
sional killers of invading pathogens to the human organism
[1]. In this regard, it was considered that only the release
of various antimicrobial and cytotoxic proteins synthesized
and distributed into different types of granules participated to
the innate immune response mediated by neutrophils. Gran-
ule types have been characterized to be readily mobilized
upon an inflammatory stimulus at the plasma membrane in
reverse order to their formation according to the formed-
first-released-last model [2]. Indeed, in the different stages
of neutrophil development, azurophil granules are formed
first followed by specific granules, gelatinase granules, and,
lastly, secretory vesicles, which are the most easily mobilized
organelles in the mature neutrophils.
Due to recent progress, this classical view has been ex-
panded by the acknowledgment that appropriately activated
neutrophils constitute a substantial source of a variety of
secreted cytokines supporting a direct contribution of these
cells in the regulation framework of the adaptive immune
response [3–5]. Neutrophils not only are a source of de
novo synthesized cytokines dependent on gene induction but
also have the capacity to express cytokines at a basal level
from preformed stores [2]. However, precise intracellular
localization of these packaged cytokines and mechanisms
underlining their secretion remain largely elusive.The widely
accepted assumption is that multiple secretory pathways
coexist in neutrophils allowing the regulated release of
diverse proinflammatorymediators [6]. Preformed cytokines
are instantly released upon ligand-receptor signaling during
the so-called “regulated exocytosis” process [7] whereas de
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novo synthesized cytokines may be released after trafficking
via recycling endosomes during the mechanism referred to
as “constitutive exocytosis” [8, 9]. Additionally, variations of
these two main classical secretion pathways have also been
reported [10]. These distinct processes selectively control
the combination of granule proteins and cytokines released
into the local microenvironment from neutrophils over a
temporal and spatial range and are thus regulatory mecha-
nisms important for the onset and resolution of inflammation
enabling the development of an appropriate inflammatory
response [11].
It is now largely recognized that neutrophil-derived
granule proteins and cytokines contribute to the mainte-
nance of the inflammatory response and, when excessively
secreted, to the ongoing process of tissue damage leading
to the development of many chronic inflammatory disor-
ders such as inflammatory bowel diseases [12], rheumatoid
arthritis [13], chronic obstructive pulmonary disease [14],
and atherosclerosis [15]. Determination of the regulatory
mechanisms mediating the different patterns of cytokine
trafficking and releasemay create opportunities to define new
targets or strategies to selectively reduce cytokine secretion in
clinical diseases.
Therefore, we selected relevant cytokines secreted by
neutrophils, described to contribute to the development of
chronic inflammatory diseases, in order to investigate their
release in combination to degranulation upon stimulation
with bacterial lipopolysaccharide (LPS).
Here, we propose an appealing model based on a linear
fitting approach of cytokine secretion and degranulation giv-
ing a first basis for deeper understanding of the relationship
between these two processes. It also provides a predictive
view on the distribution of cytokines in neutrophils and offers
an outstanding starting point to target future research on
release mechanisms involved in inflammatory processes.
2. Materials and Methods
2.1. Purification of Human Neutrophils. Peripheral blood of
healthy volunteers was collected in EDTA-containing tubes
(BD Vacutainer, BD Biosciences, Erembodegem, Belgium).
Samples were collected in accordance with the good clinical
and ethical practices, which have been approved by the
Ethics Review Panel (ERP) of the University of Luxembourg
according to the “Comite´ National d’Ethique de Recherche”
(CNER) from Luxembourg.
Neutrophils were isolated from blood samples by Poly-
morphprep separation procedure (Axis-Shield, Dundee,
Scotland) according to manufacturer’s instructions. Remain-
ing erythrocytes in the neutrophil cell suspension were lysed
for 10min with red blood cell lysis buffer (155mM NH
4
Cl,
10mM KHCO
3
, 0.1mM EDTA, and pH 7.4 [16]).
Neutrophils were washed and resuspended in PBS 1x
(pH 7.4). Purity of isolated neutrophils was analyzed by the
BD FACSCanto II flow cytometer (BD Biosciences) using
two mixtures of selection markers CD66b-FITC/CD11b-
PE/CD14-APC and CD15-FITC/CD16-PE/CD45-APC (Im-
munotools, Friesoythe, Germany) on 10,000 events in
the gated population of homogenous (FSC-A versus SSC-A),
single (SSC-A versus SSC-H), and living cells (negative cells
for Sytox Blue staining (Invitrogen, Gent, Belgium)). Purified
neutrophils are positive for all the selection markers used by
flowcytometry.Humanneutrophilswere cultured inX-VIVO
15mediumwith L-glutamine and gentamicin (Lonza) at 37∘C
and 5% CO
2
up to 24 h after purification.
2.2. Cell Stimulation. Purified neutrophils were stimulated
with bacterial LPS from E. coli serotype O111:B4 (Sigma,
Bornem, Belgium) for simulating proinflammatory condi-
tions. For kinetic studies of cytokine secretion and degran-
ulation, neutrophils were stimulated with 100 ng/mL LPS for
2, 4, 6, 12, and 24 h under serum-free conditions to avoid any
serum component contamination, which could interfere with
specific LPS-induced cell responses.
2.3. Cell Analysis by Flow Cytometry. In accordance with the
literature, the most relevant markers have been selected for
degranulation analysis [17]. Degranulation was determined
by measuring the expression of CD markers characteristic
for azurophil granules (CD63-PE), specific granules (CD15-
FITC, CD66b-FITC), gelatinase granules (CD11b-PE), and
secretory vesicles (CD13-APC, CD14-APC, CD18-FITC, and
CD45-APC) at the plasma membrane by flow cytometry (all
antibodies are from BD Biosciences except CD14-APC from
Immunotools).
IgG1-FITC, IgG2a-PE (BD Biosciences), and IgG1-APC
antibodies (Immunotools) were used as negative isotype con-
trols to place the cells in the first decade of any plot, whereas
CD45-FITC, CD45-PE, or CD45-APC (BD Biosciences) sin-
gle dye staining was used to set compensations. Data analysis
was performed bymeasuring themean fluorescence intensity
(MFI) for each CD marker with BD FACSDiva software (BD
Biosciences) on the gated population of granulocytes (FSC-
A versus SSC-A), single (SSC-A versus SSC-H), and living
cells (negative cells for Sytox Blue staining (Invitrogen)). In
total, 10,000 events were recorded per staining. The relative
translocation of CD markers to the plasma membrane for
each granule was determined by calculating the ratio between
MFI of LPS-stimulated cells and nonstimulated control from
the same time point.
2.4. Measurement of Cytokine Secretion by Cytometric Bead
Array (CBA). Density of human neutrophils was adjusted
to 10 × 106 cells per condition for subsequent quantitative
measurement of cytokine secretion by LPS-stimulated cells,
respectively. Fresh supernatants were collected and used
directly for cytometric bead array (CBA, BD Biosciences)
analysis. The multiplex standard curve composed of mixed
cytokine standards was set up by serial dilutions according to
the manufacturer’s instructions. Selected capture beads were
prepared and added to supernatants. The following beads
were used: CCL2 (MCP1, bead D8), CCL3 (MIP1𝛼, bead
B9), CCL4 (MIP1𝛽, bead E4), CCL5 (RANTES, bead D4),
IL1a (bead D6), IL1b (bead B4), IL6 (bead A7), IL8 (CXCL8,
bead A9), IL12b (bead E5), and TNFa (bead C4). After 1 h
of incubation, detection reagent was added to each sample.
Journal of Immunology Research 3
After 2 h of incubation, samples were rinsed with wash buffer
and centrifuged. Samples were washed again prior to flow
cytometry analysis (BD FACSCanto II, BD Biosciences).
Results were quantified using the standard curves and the
Flow Cytometric Analysis Program (FCAP) Array software
(Soft Flow, Minneapolis, USA).
2.5. Linear Fitting Approach via R Statistical Software.
Kinetic profiles of cytokine secretion and degranulation were
imported into R statistical software (https://www.r-project
.org/) and a linear regression approach was applied. This
approach was used to find the optimal proportionality factor,
namely, the slope of the model, and provide methods to
evaluate the significance of our models. All ratio values
between LPS-stimulated and nonstimulated control condi-
tions (stimulation points 0, 2, 4, 6, 12, and 24 h) from the
time series of cytokine secretion and degranulation were
log
10
normalized to minimize scale effect. For each granule-
specific CD marker, a linear model has been fitted with the
secreted cytokines. For each model, ANOVA analysis has
been performed and the adjusted 𝑅-squared (RSQ) value and
the slope of the model were retained. Models with a signifi-
cant difference to the null model (𝑝 value ≤ 0.05) and with a
high adjusted RSQ value between degranulation marker and
secreted cytokine (RSQ ≥ 𝑟, with 𝑟 being determined by
simulations; see Section 2) were considered as underlying a
strong similarity of pattern between a secreted cytokine and
a mobilized degranulation marker. Then, cytokines linked to
the same degranulation marker were clustered. To visualize
these clusters, time series of the degranulation marker and
its relative cytokines of the cluster were plotted. To permit
comparison between time series from different scales, values
from the secreted cytokines were divided by the slope of their
linear model.
2.6. Simulations to Determine the Optimal RSQThreshold. To
define the optimal RSQ threshold, we simulated the fitting
between pairs of granule marker and cytokine with con-
trolled perturbations between them and choose the threshold
by determining at which level of perturbation the RSQ
was drastically dropping. The simulations were designed
as follows: time series of each granule-specific marker and
cytokines were taken individually (19 time series in total)
and used to simulate matching time series with more or less
perturbations. For the six points of each time series (0, 2,
4, 6, 12, and 24 h), a random number between 𝑉
𝑖
− 𝑒 and
𝑉
𝑖
+ 𝑒 was drawn. 𝑉
𝑖
is the 𝑖th element of the time series
and 𝑒 is a predefined constant. 𝑒 controls the intensity of the
perturbation: the highest 𝑒 is the more different both profiles
are expected to be. All values from 0 to 1 with a step of 0.1
were tested for 𝑒 (0, 0.1, 0.2, etc., to 1). Then, the RSQ of
the original profile versus simulated profile was computed as
mentioned in linear fitting approach via R statistical software.
This process was repeated 1000 times and, for each of the
19 original profiles, the average of the RSQs was computed
and plotted against the 𝑒 value. To define the optimal RSQ
threshold that defines a cut-off between linear fitting models
with “highRSQ” and “lowRSQ,”we clustered the distribution
of averaged RSQ into two groups, using a 𝑘-means approach
(a silhouette analysis of all clustering solution with 2 to 10
clusters confirmed that using 2 clusters was the best solution,
data not shown). The last element of the cluster with the
highest center, namely, 0.796, was taken as RSQ threshold for
our analysis.
2.7. Statistical Analysis. Statistical analyses were performed
using the PRISM6 software (Graph Pad Software, La Jolla,
CA, USA). When normality and homogeneity of variances
were ascertained, as determined by the 𝐹-test, Student’s 𝑡-test
analyses were performed to establish two group comparisons.
Otherwise, Mann-Whitney tests were used for two group
comparisons. 𝑝 values ≤ 0.05 were considered statistically
significant.
3. Results
3.1. Cytokine Levels Secreted by Human Neutrophils upon
LPS Stimulation. Since recent reports have implicated neu-
trophils in the development of chronic inflammatory disor-
ders, we wanted to characterize the regulatory mechanisms
in the release of neutrophil-derived products. In a first step,
cytokine candidates found secreted by highly purified (≥98%)
neutrophils upon LPS stimulation [17] were selected for
integration into our mathematical model. These cytokines
have a particular relevance since they have been reported to
contribute to the development of different chronic inflamma-
tory diseases through the recruitment of diverse immune cells
to the inflammatory site (Table 1).
To develop a reliable model that investigates the relation-
ship between degranulation and cytokine secretion, differ-
ent experimental data sets were generated. Time series of
cytokine secretion were determined to serve as input to our
model. Neutrophils were treated for 0 h, 2 h, 4 h, 6 h, 12 h, and
24 h with LPS 100 ng/mL since maximal peak of secretion for
cytokines was reached at this concentration (data not shown).
Subsequent quantitative measurement of cytokine secretion
was performed by the CBA technique. A basal secretion
level of all cytokines was detected in supernatants from
neutrophils under nonstimulated conditions. Secretion of
most of the cytokines released into the extracellular medium
was augmented with increasing time of LPS stimulation,
except for IL12𝛽 andCCL5whose releasewas not significantly
affected by LPS treatment (Figure 1).
The secretion pattern was different for each cytokine in
the way that different profiles could be identified. Except
for IL1𝛼, secretion levels of cytokines were maximal 6 h
or 12 h after treatment with LPS and decreased after 24 h.
Maximal cytokine secretion was observed at (i) 6 h LPS for
CCL3 and (ii) 12 h LPS for TNF𝛼, IL6, IL8, CCL2, IL1𝛽, and
CCL4.Moreover, quantities of released cytokines were highly
variable. TNF𝛼, IL1𝛼, IL1𝛽, and CCL3 were only discretely
secreted (≤150 pg/mL) whereas IL6, CCL2, and CCL4 were
secreted at an intermediate level (∼250–600 pg/mL) and IL8
was highly secreted (≥30000 pg/mL).
3.2. Effect of LPS on Degranulation in Neutrophils. To collect
data for the implementation of the model, the second series
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Figure 1: Continued.
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Figure 1: Time-dependent effect of LPS on cytokine secretion in human neutrophils. Cytokine secretion was measured by CBA upon
stimulation with 100 ng/mL LPS for 0 h, 2 h, 4 h, 6 h, 12 h, and 24 h. Results are mean secretion (pg/mL) ± SEM of at least 3 independent
experiments, significantly different from cytokine secretion in nonstimulated control at the corresponding time: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01,
∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
Table 1: List of selected proinflammatory cytokines contributing to the development of chronic inflammatory disorders.
Cytokine Cell recruitment Chronic inflammatory disorders
TNF𝛼 Monocytes, neutrophils, and dendritic cells RA [13], IBD [18], A [19], and COPD [20]
IL1𝛼 Neutrophils, T cells RA [21], IBD [22]
IL1𝛽 Neutrophils, thrombocytes, and T cells RA [13]
IL6 Neutrophils, B cells RA [13], A [23], and COPD [24]
IL12𝛽 T cells RA [25], IBD [26], and A [27]
CCL2 Monocytes, dendritic cells, and memory T cells RA [21], A [28]
CCL3 Neutrophils, eosinophils, and basophils RA [29], A [30]
CCL4 Monocytes, dendritic cells, NK cells, and T cells RA [31], IBD [32], and A [30]
CCL5 Eosinophils, basophils, and T cells RA [33], A [30]
IL8 Neutrophils, macrophages, and mast cells RA [13], A [28], and IBD [34]
RA = rheumatoid arthritis, IBD = inflammatory bowel disease, A = atherosclerosis, and COPD = chronic obstructive pulmonary disease.
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Figure 2: Continued.
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Figure 2: Temporal pattern of degranulation upon LPS stimulation in human neutrophils. Translocation of degranulation markers to the
plasma membrane was assessed using flow cytometry after cell treatment with 100 ng/mL LPS for 0 h, 2 h, 4 h, 6 h, 12 h, and 24 h. Sytox Blue
negative cells were gated to exclude dead cells from the analysis. Results are expressed inmean fluorescence intensity (MFI) of LPS-stimulated
cells and nonstimulated control ± SEM of at least 3 independent experiments, significantly different from nonstimulated control at the same
time point: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
of experiments consisted in identifying the kinetic degran-
ulation profile of the different granule types upon time-
dependent LPS stimulation. Degranulation can be deter-
mined by the upregulation of granule membrane molecules
as a consequence of membrane fusion from granules with
the plasma membrane [35]. Therefore, LPS-treated cells were
analyzed for cell surface expression of several CD molecules
known as degranulation markers.
Results showed that LPS stimulation affected the ease of
mobilization of intracellular granule types in neutrophils in
a time-dependent manner, as reflected by increased translo-
cation of CD markers to the cell surface (Figure 2). In a
temporal pattern, LPS stimulation induced the release of
specific granules as demonstrated by the redistribution of
CD15 and CD66b to the plasma membrane. Translocation
of these CD markers towards the plasma membrane was
scattered over a time interval of 4 h and 24 h.
In a similar way, LPS stimulation increased the presence
of CD11b as well as CD13, CD18, and CD45 at the plasma
membrane reflecting an increased release of gelatinase gran-
ules and secretory vesicles, respectively. As observed with
CD15 and CD66b for the specific granules, increase of these
CD markers was detected between 4 h and 24 h of LPS
stimulation.
Maximal expression at the plasma membrane for all the
CD markers was detected after 6 h or 12 h of LPS stimulation
(Figure 2).
It must be noted that LPS was unable to trigger the
mobilization of azurophil granules since CD63 expression
was not changed at the plasma membrane.
3.3. Linear Fitting of Cytokine Secretion and Degranulation
Kinetics. Many approaches exist for the examination of time
series of expression data (e.g., [36]) but none of them could
be applied to analyze short-time series of secretion. For this
reason, we used a novel model approach to explore the
relationship between cytokine secretion anddegranulation by
their kinetic profiles (Figure 3).
We hypothesized that time series of secreted cytokines
with similar pattern to time series of degranulation markers
present at the plasma membrane should have proportional
values at each time point of LPS stimulation, so that a
proportionality factor between the two profile curves can
be defined. To address this question, we choose to use the
linear regression approach, which fits best to our needs: it
captures proportionality well, can be used with only one
pair of profiles (in our case, cytokine versus granule-specific
marker), and includesmeasures to evaluate the results (signif-
icance of the model and𝑅-squared value, Section 2). All ratio
values between LPS-stimulated and nonstimulated control
conditions from the time series of cytokine secretion and
degranulation (Table 2) were log
10
normalized.
While the ANOVA analyses the efficiency of this model
(i.e., proportional kinetic profile curves are significantly
different from the null model), the adjusted RSQ value
measures the correlation between the kinetic profiles (i.e.,
proximity to the linear fitting). The optimal RSQ value was
determined by simulations, in which predefined perturba-
tions were introduced to our kinetic profiles (Section 2).
How augmenting perturbations (𝑒 from 0 to 1) influenced
the linear fitting of two time series, in our example, the linear
fitting between the granule marker CD11b and the cytokine
IL8, is presented in Figure 4(a). The original kinetic profile is
depicted by the black line whereas the one with perturbations
is represented by the red line. By plotting the average RSQ
values (derived from 1000 repetitions of simulations) against
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Table 2: Time-dependent (a) secretion of cytokines and (b) granules expressed in ratio between LPS-stimulated and nonstimulated cells ±
SEM of at least 3 independent experiments, significantly different from nonstimulated control at the same time point: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01,
∗∗∗
𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
(a)
Relative secretion 0 h LPS 2 h LPS 4 h LPS 6 h LPS 12 h LPS 24 h LPS
TNF𝛼 1.28 ± 0.28 6.30 ± 1.81∗ 24.82 ± 8.26 51.54 ± 14.79 36.70 ± 11.20∗∗∗ 16.48 ± 11.35
IL1𝛼 0.73 ± 0.38 1.43 ± 0.21 3.36 ± 1.92 6.84 ± 4.92 6.67 ± 3.51∗∗∗ 14.70 ± 8.51∗
IL1𝛽 0.69 ± 0.69 1.64 ± 0.2∗ 4.87 ± 2.55 8.45 ± 5.89 7.89 ± 2.3∗ 4.20 ± 3.46
IL6 0.93 ± 0.18 1.30 ± 0.37 34.35 ± 23.38∗ 69.92 ± 50.91∗ 185.53 ± 62.99∗∗∗ 23.64 ± 10.51∗
IL12𝛽 1.02 ± 0.06 0.88 ± 0.04 1.06 ± 0.09 1.16 ± 0.19 6.20 ± 3.57 1.08 ± 0.25
CCL2 0.97 ± 0.13 0.86 ± 0.17 1.11 ± 0.18 1.17 ± 0.36 6.43 ± 1.48∗∗ 1.69 ± 0.66
CCL3 1.43 ± 1.43 6.72 ± 0.98∗∗ 24.35 ± 4.51∗ 66.06 ± 17.86∗ 65.98 ± 24.41∗∗∗ 11.05 ± 4.62
CCL4 1.06 ± 0.07 2.65 ± 0.76 8.10 ± 3.09∗ 11.69 ± 5.84∗ 69.14 ± 15.76∗∗∗ 1.22 ± 0.72
CCL5 0.88 ± 0.05 1.07 ± 0.24 1.04 ± 0.34 0.89 ± 0.22 0.96 ± 0.18 1.05 ± 0.29
IL8 1.02 ± 0.12 4.89 ± 1.47∗ 9.85 ± 2.31∗ 15.84 ± 3.93∗ 31.83 ± 10.15∗∗∗ 27.00 ± 8.89∗
(b)
Relative degranulation 0 h LPS 2 h LPS 4 h LPS 6 h LPS 12 h LPS 24 h LPS
CD63 1.00 ± 0.42 1.09 ± 0.33 0.97 ± 0.10 1.02 ± 0.12 0.88 ± 0.10 0.92 ± 0.12
CD15 1.00 ± 0.07 1.08 ± 0.14 1.26 ± 0.06∗∗ 1.23 ± 0.07 1.56 ± 0.13∗∗ 1.36 ± 0.16
CD66b 1.00 ± 0.06 1.14 ± 0.13 1.37 ± 0.12 1.72 ± 0.14∗∗∗ 2.41 ± 0.13∗∗∗ 1.87 ± 0.20∗∗
CD11b 1.00 ± 0.17 1.29 ± 0.14 1.62 ± 0.09∗∗ 2.11 ± 0.21∗∗∗ 2.57 ± 0.29∗∗∗ 2.03 ± 0.34∗
CD13 1.00 ± 0.13 1.08 ± 0.10 1.14 ± 0.13 1.38 ± 0.14∗ 1.94 ± 0.31∗ 1.76 ± 0.32
CD14 1.00 ± 0.30 1.13 ± 0.33 1.31 ± 0.37 1.58 ± 0.44 1.23 ± 0.35 1.00 ± 0.31
CD18 1.00 ± 0.14 1.26 ± 0.26 1.23 ± 0.17 1.61 ± 0.3 2.22 ± 0.33∗∗ 1.68 ± 0.27∗
CD45 1.00 ± 0.12 1.19 ± 0.15 1.39 ± 0.11∗ 1.58 ± 0.16∗ 2.18 ± 0.10∗∗∗∗ 1.84 ± 0.22∗∗
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Figure 3:Workflow of linear fitting of LPS-mediated cytokine secretion and degranulation. A novel approach based on linear fitting was used
to find linear relationship between short-time series of secreted cytokines and similar pattern to degranulation markers present at the plasma
membrane. After importing data into R statistical software, all ratio values between LPS-stimulated and nonstimulated control conditions
were log
10
normalized and treated as mentioned in Section 2.
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Figure 4: Continued.
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Figure 4: Linear fitting approach to investigate time series of degranulation and cytokine secretion. (a) Simulationswere performed to find the
optimal threshold for RSQ value. After introducing perturbations (𝑒 value) to the kinetic profiles, the linear fitting decreases in significance.
(b) Plot of average RSQ deriving from simulations against augmenting 𝑒 values. (c) Perfectly linear fitting model in which the behaviour of
IL8 is correlated to CD11b. Due to its 𝑝 value of 0 and RSQ of 0.91, the correlation between IL8 and CD11b corresponds to a perfect linear
fitting model.
𝑒 values, 𝑘-means clustering can differentiate between “high”
(black) and “low” (red) RSQ (Figure 4(b)).
By setting these parameters nonsignificant outcomeswith
“low” RSQ were eliminated, and the threshold for RSQ was
set to RSQ ≥ 0.796.
An example of a significant linear fitting model is shown
(Figure 4(c)), in which the behaviour of IL8 is correlated to
CD11b. Due to its 𝑝 value of 0 and RSQ of 0.91, the correlation
between IL8 and CD11b fits to the model.
3.4. Relationship between Degranulation and Cytokine Secre-
tion. After filtering only highly significant correlation data,
results from human neutrophils were plotted. The granule
membrane molecules (CD63, CD66b, CD11b, and CD45),
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Figure 5: Linear fitting of LPS-mediated kinetics of cytokine release and degranulation in human neutrophils. Enlisted cytokines on the
histograms fitted to the kinetics of the degranulation markers characteristic for (a) azurophil granules (CD63), (b) specific granules (CD66b),
(c) gelatinase granules (CD11b), and (d) secretory vesicles (CD45), according to the selection of 𝑝 value ≤ 0.05 and RSQ ≥ 0.82.
specific of each type of granule, that are most highly upreg-
ulated have been targeted to show the linear fitting approach
(Figure 5).
This method applied to the time series data showed that
the secretion of three selected proinflammatory cytokines
(IL8, IL6, and IL1𝛽) strongly correlated with the release of
secretory vesicles, gelatinase granules, and specific granules
(Figure 5).
The release of the cytokine IL8 fitted to CD66b suggesting
that secretion of this cytokine correlated to specific granules
(Figure 5(b)). Moreover, time series of IL1𝛽, IL8, and IL6
release were strongly correlated to the degranulation marker
CD11b, showing a relationship between gelatinase granules
and these cytokines (Figure 5(c)).
Furthermore, secretory vesicles represented by the
marker CD45 were fitted to IL8 (Figure 5(d)).
Since no significant cytokine correlation has been
observed for CD63, azurophil granules are probably not
associated with cytokine secretion (Figure 5(a)).
4. Discussion
For many years, the contributory impact of neutrophils to
the development of chronic inflammation was not seriously
taken into account since they have been considered as termi-
nally differentiated cells synthesizing low amount of RNAand
protein [37]. However, the vast number of neutrophils found
at the site of infection cannot be neglected due to the fact
that their secreted amounts of granule proteins and cytokines
exert a cumulative and synergistic effect on the inflamma-
tory tissue environment [15]. These proinflammatory soluble
mediators are highly decisive for the onset of inflammatory
processes and the activation and the recruitment of various
immune cells to the infection site [1]. However, little is known
about the combination in which cytokines and granule
proteins are secreted by neutrophils. In the present report,
we therefore aimed to predict the spatiotemporal regulation
of proinflammatory mediator release in neutrophils. For this
purpose, LPS has been used as stimulus agent since it has been
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well described to induce the secretion of granule contents
and cytokines [17, 38]. Once the model is established, it could
constitute an important tool to investigate other stimulation
conditions (fMLF, TNF𝛼, IL8, or combination of stimuli)
in order to mimic different microenvironmental conditions
(e.g., healthy and pathological diseases) and help to improve
our knowledge of inflammatory processes.
Our study is the first to propose an original approach
allowing the establishment of a relationship between cytokine
secretion and degranulation in neutrophils.We choose to use
the linear fitting approach to integrate data generated from
own experiments and obtained from LPS-mediated short-
time series of degranulation and cytokine secretion. Other
approaches, such as Pearson correlation, are based only on
the average of all values correlated. In contrast, our model is
able to reliably predict time-specific associations between the
two dynamic functions in neutrophils, respecting each time
point of stimulation. According to our results, a number of
cytokines could be fitted to the different types of neutrophil
granules. These granules have been characterized to be
mobilized towards the plasma membrane in a hierarchically
andmore precisely reverse order to their formation according
to the formed-first-released-last model [2]. Our model illus-
trates the fact that neutrophil-derived cytokines and granules
are released in a hierarchical sequence in accordance with
their roles during the microbial elimination processes and
inflammatory response (Figure 6(a)).
In this study, the linear fitting approach (i) gives us infor-
mation about the concurrent behavior of cytokine secretion
and degranulation upon inflammation, thus underlining the
key role of both functions in the regulation of inflamma-
tory responses and (ii) can represent an attractive method
to investigate the possible mobilization or localization of
cytokines in the different types of granules.
Given that cytokines can exert pleiotropic functions,
some of them are probably localized in different types of
granules as suggested by our model. In this sense, we found
that IL8 correlated to secretory vesicles (Figure 6(a)), which
are the most easily mobilized organelles in mature neu-
trophils [35]. Furthermore, IL8 was correlated to gelatinase
and specific granules. These data support the observations
of Pellme´ et al. [2], who reported that IL8 is stored in
cytoplasmic granules in resting peripheral blood neutrophils
and, thus, can be rapidly mobilized and released by the cells.
IL8 can be secreted into the extracellular milieu from
intracellular stores or by de novo synthesis via the classi-
cal secretory pathway. Two phases of secretion have been
described: an early secretory phase which is directly induced
by LPS and a late secretory phase which results from LPS-
stimulated release of other proinflammatory mediators such
as TNF𝛼 and IL1𝛽 [39]. The fact that IL8 is stored in different
types of granules could allow its secretion over a large time
interval.
Large amount of IL8 released could be explained by a
positive feedback loop generated by MMP-9 on the IL8-
induced neutrophil activity. Indeed, it has been previously
reported that MMP-9 released from gelatinase granules is
able to process IL8 [40] which is stored in the same granules
as MMP-9 before secretion as shown by our linear fitting
approach. IL8 cleaved by MMP-9 can enhance neutrophil
degranulation [40], in comparison to nondegraded IL8, and
thus increase the quantity ofMMP-9 and IL8 released leading
to an amplification of this system.
Our results also show a significant fitting between kinetics
of IL6 secretion and the release of gelatinase granules. In
line with this observation, Terebuh et al. [41] showed by
immunohistochemical staining of neutrophils that IL6 might
be localized in gelatinase granules and secretory vesicles.
Finally, in our model, IL1𝛽 could be fitted to gelatinase
degranulation as previously postulated [17]. IL1𝛽 is secreted
by a nonclassical secretory pathway (independent of endo-
plasmic reticulum and Golgi apparatus). Different release
models have been suggested for IL1𝛽 [42] but themechanisms
associated are poorly understood and still controversially
discussed. Our data indicate that the process of IL1𝛽 secretion
involves a trafficking via granules which could be related to
gelatinase granules.
In contrast to other granules, degranulation of azurophil
granules seems unchanged by LPS suggesting that either (i)
this granule typemay require further cell activation to induce
its mobilization towards the plasma membrane [43] or (ii)
the upregulation of CD63 at the plasmamembranemight not
be significant enough to detect since azurophil granules are
rather poor in receptors in contrast to secretory vesicles [35].
For this reason, no cytokine could probably be fitted to CD63
in human neutrophils.
In this view, late release of azurophil granule contents
can be explained by the involvement of these proteins in
neutrophil extracellular trap formation [43]. In this regard,
the role of these granules during cytokine secretion appears
very restricted. This assumption is supported by our results
showing that azurophil granules are not able to translocate to
the plasma membrane upon LPS stimulation in neutrophils.
5. Conclusion
Intracellular localization of cytokines in neutrophils remains
largely elusive due to the fact that reliable staining for
electron microscopy is facing challenges as the low intra-
cellular amount of cytokines and other techniques used to
document subcellular organelle location of cytokines have
limited resolution (e.g., subcellular fractionation) [44].
In comparison to the modelling approach proposed by
Rørvig et al. [45], which is based on proteomic and mRNA
array data to predict localization of proteins in granules,
our approach is complementary by including functional data
analysis. Hence, the linear fitting between degranulation and
cytokine release in LPS-treated neutrophils represents an
attractive method to investigate the possible localization of
cytokines in the different types of granules even if additional
experiments are required to confirm the intracellular local-
ization of cytokines. Furthermore, since our linear fitting
approach has been adapted to investigate secretion kinetics, it
can easily be extrapolated for the analysis of other short-time
series deriving from other cell types, disease, or developmen-
tal states, for example, protein arrays or proteomics data.
Our linear fitting approach primarily constitutes a
tool aiming to investigate regulatory mechanisms during
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Figure 6: Hypothetical models of fitted cytokines and granules in human neutrophils. (a) Neutrophil-derived cytokines are released in a
hierarchical sequence coincident with the roles of granules (IV secretory vesicles, III gelatinase granules, II specific granules, and I azurophil
granules) during the microbial elimination processes and inflammatory response. (b) Cytokines and granules are released in a concurrent
fashion but could additionally be localized in or mobilized to the different granule types. Classical secretory pathways are mediated through
the endoplasmic reticulum (ER) andGolgi complex (IL6 and IL8). IL1𝛽 is secreted on a nonconventional pathway. Possible routes for cytokine
trafficking (after ER-Golgi or after cleavage) and mobilization to the plasma membrane relative to degranulation are shown in red. Different
types of granules are characterized by their CDmarkers and proteolytic enzymes (triangles): CD63, myeloperoxidase (MPO), and neutrophil
elastase (NE) for azurophil granules; CD66b and lactoferrin (LTF) for specific granules; CD11b and matrix metallopeptidase-9 (MMP-9) for
gelatinase granules; and CD45 for secretory vesicles. Uponmobilization of the granules to the plasmamembrane, granule docking and fusion
lead to the translocation of the CD markers to the plasma membrane and the release of proteolytic enzymes.
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neutrophil exocytosis but can also serve as basis to identify
regulatory proteins by the supplementary analysis of proteins
involved in exocytosis (e.g., SNARE and Rab proteins) and
the construction of a dynamic regulatory network [46].
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